The testicular-hypothalamic-pituitary axis regulates male reproductive system functions.
INTRODUCTION
The hypothalamus, pituitary and testes produce endocrine hormones responsible for regulation of the prostate and other male sexual functions (12, 46) . Exogenous endocrine active compounds can disrupt these processes. Some pesticides (e.g., vinclozolin and linuron) are known to have antiandrogenic activity (19, 20) . Toxic effects of antiandrogens in male rodents range from developmental effects, such as reproductive malformations, retained nipples and undescended testes, to pubertal effects, such as delayed puberty and reduced weights of prostate and other reproductive organs. In the pharmaceutical setting, therapeutic drugs such as finasteride, dutasteride, bicalutamide, and flutamide are used to treat benign prostatic hyperplasia and/or prostate cancer by inhibiting androgen-dependent growth processes.
The mechanisms of action of antiandrogens are generally of two forms. The first is the androgen antagonist, which binds to the AR but does not stimulate DNA transcription, such as the pharmaceutical compounds flutamide and bicalutamide, or the environmental compound vinclozolin. The second is the 5 -reductase inhibitor, which blocks the metabolism of T to DHT. The therapeutic drugs dutasteride and finasteride are examples of 5 -reductase inhibitors; no environmental examples are currently known. Both of these mechanisms effectively inhibit AR-mediated DNA transcription, leading to reduction of prostate size and cell numbers and decreased prostatic fluid production. Quantification of the male regulatory processes and their disruptions would aid in the dose-response assessment of environmental endocrine active compounds (4, 5) . This requires biologically based quantitative methods describing not only the pharmacokinetics and mode of action of the exogenous compound of interest, but also the pharmacokinetics of the endogenous hormones and how they regulate the male reproductive organs.
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The objective in this research effort was to understand the normal adult male hormonal regulation of the prostate to set a foundation for quantitatively characterizing the effects of exposure to antiandrogens in male rats. To quantitatively understand the normal adult male hormonal regulation of the prostate, mathematical descriptions of the kinetics of testosterone (T), 5 -dihydrotestosterone (DHT) and luteinizing hormone (LH) are required, along with several pharmacodynamic components, such as prostatic androgen receptor (AR) concentrations, maintenance of prostate size, and regulation of prostatic fluid production.
The regulation of T is crucial for prostate maintenance in that the size and function of the prostate is gene-regulated via DNA binding by androgen-bound AR (21-23, 37, 42, 53) . T is mainly produced in the testicular Leydig cells in response to LH released from the pituitary (12) .
It is metabolized to DHT by 5 -reductase in the liver and prostate (39, 50) . The enzyme 5 -reductase is upregulated by T and DHT via AR-mediated gene expression (39, 50) . LH upregulates the production of T and hence DHT, which, in turn, downregulate LH, creating a negative feedback loop (12) . In the blood, T and DHT bind to serum albumin, which appears to play a role in regulating transport and tissue uptake dynamics (15, 33, 49) .
In this article, a model describing the endogenous hormone kinetics of the testicularpituitary axis and the dynamics of the androgenic regulation of the prostate is presented. The model includes the pharmacokinetics of T, DHT and LH, as well as the dynamics of AR binding and signaling as they relate to the regulation of the prostate. Development of the model included characterization of critical biological and physiological processes inherent in the hormonal regulation of the male reproductive system, including androgen-LH feedback loops and ARmediated regulation of the prostate.
The model structure for the hormonal transport, or pharmacokinetic component, is based on standard physiologically based pharmacokinetic (PBPK) modeling (32), while the dynamics of the AR-based regulation of the prostate are based on mass action kinetics. These dynamics include binding of T and DHT to the AR, dimerization of androgen-AR complexes, and gene activation by these complexes via DNA binding. The complexes regulate prostatic cellular mass, fluid production, blood flow, AR concentrations and 5 -reductase activity.
Unknown physiological, kinetic and binding parameters were estimated using available experimental data from the literature. The resulting calibrated model is capable of quantitatively describing intact and castrated rats at steady-state, as well as the dynamics that occur following castration. This model may be used for testing and generating hypotheses, data interpretation, experimental design and identifying key data gaps in the study of the hormonal regulation of the prostate, and provides a framework for elaborations that address the effects of exposure to exogenous, pharmaceutical or environmental androgens and antiandrogens (5) .
METHODS
Model structure: Pharmacokinetic component. The transport and dispositional kinetics of T and DHT are described using standard PBPK compartmental modeling (32), while a single compartmental model is used for LH. Flow-limited compartments are utilized in cases where the uptake rate of a compound into a tissue is limited by the blood flow rate into the tissue rather than the diffusion rate of the compound across cell membranes. Conversely, diffusion-limited compartments are used when the diffusion across cell membranes is slow compared to the blood flow rate into the tissue (32). The pharmacokinetics of T and DHT are modeled with compartments representing the systemic serum, liver, prostate, testes and rest of body (see Figure 1 ). LH is modeled with a single systemic compartment that captures androgen-regulated synthesis and the effects of LH on T synthesis in the testes. All terms in the equations are defined in Tables 1-4 .
Systemic serum compartment. The compartment for systemic serum includes exchange of T and DHT with the tissue compartments, the binding dynamics of T and DHT to albumin, and a basal input rate of T, due to limited synthesis of T outside the testes (29). A simplifying assumption is made that all concentrations are rapidly equilibrated between red blood cells and serum.
The rate equation for the kinetics of T in the systemic serum is given as: 
The first four terms represent T exchange with the rest of body, prostate, liver and testes compartments respectively, followed by the basal synthesis of T. Free concentrations CT blf are affected by albumin binding in the blood as in Eq. 3 below. It is assumed that only free T is available to enter the testes and rest of body compartments, while both free and albumin-bound T are available for uptake into the metabolically active prostate and liver (33).
The equation for the kinetics of DHT in systemic serum has a similar form, except that basal DHT synthesis is not included since it is assumed that all significant amounts of DHT are produced in the prostate and liver via metabolism (1) . In addition, the rest of body compartment for DHT incorporates the testes, which is modeled as a separate compartment for T to capture the dynamics of T synthesis. The equation for DHT transport in the systemic serum is given by:
We assume standard binding kinetics for T and DHT binding to albumin:
: :
with free T, DHT and albumin concentrations determined using mass balance:
:
Liver compartment. The kinetics of T and DHT in the liver are described using a flowlimited compartmental model. Metabolism of T to DHT via 5 -reductase in the liver is modeled with a Michaelis-Menten term, and linear terms are included for the general metabolic clearance of T and DHT in the liver (49). The rate equations for T and DHT in the liver are given by:
Free concentrations of T and DHT in the liver are given by the algebraic equations:
so that free concentrations are proportional to total concentrations.
Testes compartment. The testes compartment has a unique structure based on the specific biology of the testes that is important for T since the testicular Leydig cells are the major source for T synthesis (12) . Here we give a brief outline of the model; for a comprehensive development of the model structure and equations, the reader is referred to Barton and Anderson, 1998 . As previously mentioned, the kinetics of DHT in the testes are incorporated in the rest of body compartment, so that the testes compartment is utilized only for T.
The testes compartment is divided into two subcompartments, representing the seminiferous tubules (ST) and the interstitial fluid (IF). To account for the testicular shunt (30)
that directs a portion of the blood flow directly into the spermatic cord (bypassing the testes), the blood flow rate to the testes compartment is split into two components (see Figure 1 ). One there is a source of T production in the IF (12) . Recalling that LH upregulates T synthesis in the Leydig cells (6), we assume a positive linear feedback mechanism in the model with rate constant k 1T . Once the testicular venous blood leaves the testes compartment, it immediately reenters the systemic serum via the spermatic cord. The rate equation for T in the IF subcompartment is given by:
With only diffusion occurring in the ST compartment, the corresponding rate equation is defined as:
The algebraic equation for the testicular venous blood describes the concentration of T as proportional to the concentration in the interstitial fluid due to nonspecific binding, and is given by:
Prostate compartment. The prostate is a complex tissue with multiple lobes and multiple cell types, which vary in their androgen responsiveness (41). The model currently is parameterized to describe the ventral lobe of the prostate, which represents 60 -70% of the rat prostate (11) . The prostate compartment includes transport to and from the blood, the metabolism of T to DHT by 5 -reductase, and the dynamics of AR binding, dimerization and DNA binding (see Figure 3) . The rate equations for the kinetics of T and DHT in the prostate are given (respectively) by:
Free prostatic T and DHT are available to bind to AR. The androgen-bound AR complexes T:AR and DHT:AR then form homo-and hetero-dimers. These dimers bind to DNA and stimulate the regulation of various processes. The equations for T and DHT binding to AR are given by:
The homo-and hetero-dimers (abbreviated as DT, DD and TT) have similar kinetics:
The dimers above are able to bind to DNA sites to form DNA-dimer complexes. In the model, there are four distinct DNA binding sites that are involved in regulating 5 -reductase synthesis, cell proliferation, apoptosis and prostatic fluid production. Although numerous genes are likely responsible for the regulation of the last three processes, in the model, the simplifying assumption was made to represent each process by a single gene.
The four representative genes in the model are available to bind to all three dimer types, yielding 12 equations for the concentrations of the DNA-dimer complexes. One example is given here. The following equation is for the concentration of the DHT:AR-DHT:AR dimer bound to the 5 -reductase synthesis-regulating gene:
where parameters and variables for the twelve DNA-dimer complexes are given in Tables 1,2 and 4. The dissociation rates for the DNA-dimer complexes are determined to reflect relative potencies between T and DHT, as well as between the four representative DNA binding sites.
Specifically, we assume that the relative potencies for the dissociation of DNA from the dimers 
LH pharmacokinetics. The kinetics of LH are described in the model with a single equation that incorporates the synthesis and elimination of LH in the serum. The synthesis of LH is negatively regulated by T and DHT concentrations, with a small basal amount of synthesis assumed. Similar to the up-regulation of T by LH, we assume a piecewise-linear feedback mechanism to describe down-regulation of LH by T. Elimination of LH is proportional to the amount of LH in the system. The transport equation is given by:
where T and D represent the relative potency for inhibiting LH production, k LH1 and k LH2
describe the decline in LH with increasing androgen, k LH3 denotes the minimum LH synthesis rate, and k LH4 represents LH degradation. See Figure 2 for a representative graph of the LH synthesis rate function. 
AR concentrations.
Although AR has been shown to be upregulated by androgens (48),
here we make the simplifying assumption that prostatic AR is produced at a constant rate and free AR is eliminated at a linearly proportional rate. We further assume that androgen-bound AR is not available for elimination. The equations for total AR amount and concentration, respectively, are as follows:
Recall the concentration of free prostatic AR is given in Eq. 24.
Prostatic blood flow.
Although it has been shown that prostatic blood flow decreases almost immediately after castration (45), here we make the simplifying assumption that the blood flow to the prostate is proportional to the volume of the prostatic cell mass V pc :
5 -reductase activity. The activity of 5 -reductase, and hence the metabolism of T, is regulated by AR binding and signaling (18, 43). Here we assume that V max is directly proportional to the occupancy, DNAo 5a , of the representative 5 -reductase gene:
Androgen-sensitive prostatic cellular mass. Based on experimental data (11, 42), we assume that the prostate contains a basal cellular mass VPC 2 that is not affected by androgens, and an androgen-sensitive cellular mass that is regulated via the occupancy of the representative cell proliferation and apoptosis genes (see Figure 4 ). The equation for the volume of the androgen-sensitive cellular mass is as follows:
This is based on the assumption that the proliferation rate is proportional to the occupancy DNAo cp of the representative cell proliferation gene, and that the rate of cell formation increases with prostate cellular mass. Moreover, the death rate is negatively related to the occupancy DNAo cd of the representative apoptosis gene, since in this case DNA occupancy results in protection from apoptosis (36) .
Androgen-sensitive prostatic ductal lumen mass. As with the prostate cellular mass, we assume there is a basal amount VPL 2 of the ductal lumen that remains unaffected by androgen concentrations, and an androgen-sensitive amount that is regulated by the representative fluid production gene in the model. The governing equation is given by:
( )
The growth rate of the ductal lumen is proportional to the occupancy DNAo sec of the representative fluid production gene and the size of the androgen-sensitive prostate cellular mass relative to the intact, steady-state cellular mass VPC 1b . Specifically, when cellular mass decreases following castration or antiandrogen exposure, the rate of fluid production concurrently decreases since there are less cells present to secrete fluid. We also assume that there is linear degradation of ductal lumen as fluid exits the prostate.
The rate constants for cell proliferation and apoptosis in equation Eq. 33 were chosen so that both terms of the equation are equal when the model reaches intact steady-state values, thus yielding equilibrium and no change in prostate cellular mass. The rate constants for fluid secretion and fluid flow in equation Eq. 34 were chosen similarly so that the entire ventral prostate is at equilibrium when steady-state values are reached.
Note that in equations Eq. 33 and Eq. 34, the ratio VPC 1 (t)/VPC 1b could become unbounded under conditions of supernormal hormone levels and prostate growth. However, in the scope of these modeling efforts, supernormal hormone levels will not be simulated and therefore supernormal prostate volumes are not expected. If one were to use the model under conditions of supernormal hormone levels, it would be necessary to address this limitation, likely using experimental data from androgen implant experiments in intact and castrate rats to define an appropriate function.
Algebraic equation for the volume of the prostate.
Adding the basal and androgensensitive volumes of the prostate cellular mass and ductal lumen mass in the model, we are able to compute the total volume of the prostate as a function of time: experimental data and a selected set were re-estimated using standard least squares parameter estimation techniques (51).
One parameter estimation problem was formulated to estimate pharmacokinetic parameters such as tissue:blood partition coefficients and the feedback parameters for LH and testosterone synthesis. These parameters were estimated using a submodel that contains only the pharmacokinetics of T, DHT and LH without any of the pharmacodynamic phenomena. The estimation problem involved comparing submodel simulations to intact and castrate steady-state values and data as in (6) .
A second parameter estimation problem was formulated with the full model to estimate pharmacodynamic parameters such as binding constants, prostatic fluid production rate, 5 -reductase V max , and prostatic cell proliferation and death rates. These parameters were estimated in comparison to intact and castrate steady-state behaviors and the dynamics of prostate regression following castration.
The third and final estimation problem was formulated with the full model and included all parameters estimated in the first two estimation problems, where the initial value for each unknown parameter was the optimal value obtained from the respective previous estimation problem. This allowed for a more accurate fit to the overall model since a submodel was used in the first problem to estimate reasonable starting points for the pharmacokinetic parameters.
Model fits using the final parameter values are presented in the results section. A complete list of model parameters with values and references is given in Tables 2-4 .
RESULTS
The model was used to predict the dynamics of androgen levels and prostate regulation under various conditions, including the intact steady state, exogenous dosing of T via intravenous injections, and castration. The simulations reported in this section vary in time duration from 8 hours to 30 days. Although rats grow significantly in the time span of 30 days and the prostate grows at a similar rate to the whole body (8, 37), we assume a constant body mass in the model, and report all simulations and experimental data as fractions of intact values.
Predicting steady-state concentrations. Figure 5 , which depicts time courses for T and LH concentrations in blood and T concentrations in the testes. The plots illustrate the ability of the model to simulate T and LH regulation in serum and the testes after a perturbation of the intact steady-state system. Note the immediate spike in serum T concentrations from the steady-state concentration of 7.6 nM, and the resulting acute decrease in serum LH concentrations, followed by decaying oscillatory effects due to the stabilizing ability of the feedback system. After approximately 4 hours from the time of injection, the system is essentially stable.
Simulating serum T levels after castration. Systemic T concentrations drop rapidly following castration (9, 26) . Within the first 30 minutes, data show serum T levels drop to approximately 15% of intact values. After 6 hours, serum T levels are reported to be less than 5% of intact values. showing a good match between the data and the model.
As illustrated by the experimental data presented in Figures 6-9 , there is a clear sequence of regulatory events that occurs after castration leading to decreased prostate weight. Within one hour there is a sharp decrease in serum androgen concentrations, followed by a drop in prostatic AR levels over a couple of days. As AR concentrations decrease, the prostate responds more slowly with decreased fluid production, so that the ductal lumen mass shrinks to less than 10% of the intact mass within a week. Finally, the prostatic cellular mass regresses at a slower pace, reaching its minimum approximately two weeks after castration. These dynamics, which are
shown together with corresponding model simulations in Figure 10 , are consistent with a generegulatory delay in the prostatic response to androgen removal.
Model validation. The predictive accuracy of the model was tested by comparing simulations to experimental data that were not used in the calibration process. These include prostatic blood flow rate measurements after castration, as well as additional data for postcastration regression of the prostate. Figure 11 depicts model simulations compared to the additional prostate weight and blood flow data. The model accurately predicts the prostate weight data, although it over-predicts the weight at 72 hours post-castration. The data from these two studies at this particular time point happen to be significantly lower than data at the same point from the studies used to calibrate the model (see Figure 8 ), which explains why the model is over-predicting the new data.
Moreover, the model predictions for prostatic blood flow rate after castration are reasonably accurate in comparison to the data ( Figure 11 ). Note that no prostatic blood flow data were used in the model calibration process, so that the accurate prediction of prostatic blood flow helps to further validate the model as a plausible representation of the biology. Since the current state of the model approximates the relationship between blood flow and tissue volume without describing the complex causal relationship (24), these results may further suggest that the simplified description provides a reasonable approximation of prostatic blood flow behavior.
DISCUSSION
The objective of this research effort was to understand the normal adult male hormonal regulation of the prostate as a foundation for quantitatively characterizing the effects of environmental or pharmaceutical antiandrogen exposure in male rats. Since it is impossible to capture all physiological and biological details in a mathematical model, a typical approach is to describe the critical determinants of biological behavior, while reasonably simplifying many other details. The result is a model that is a mix of mechanistic and empirical elements. The goal is then to obtain a parameter set that produces biologically plausible behavior and that matches well with available experimental data. This model has 25 unknown parameters that needed to be estimated in comparison with experimental data. This must be addressed carefully to minimize problems of mathematical illposedness and to maximize the biological plausibility of the model. Parameter estimation problems often are subject to ill-posedness, which means that there may not be a solution to the problem, there may be more than one solution, or the problem may be highly sensitive to perturbations in data or parameters (25).
In this case, the unknown parameters first were separated into two subsets based on function and estimated using two separate estimation problems. As described in the Methods section, the pharmacokinetic parameters were estimated by comparing a pharmacokinetic submodel to measurements of steady-state androgen concentrations as in (6), while the pharmacodynamic parameters were estimated using the full model in comparison to steady-state concentrations and measurements of post-castration dynamics.
This approach helped address ill-posedness by splitting the estimation into two problems, effectively reducing the size of the unknown parameter space for each problem. Moreover, the parameters to be estimated were grouped with experimental data that are more directly related to the relevant biology for each parameter subset (pharmacokinetic vs. pharmacodynamic).
Incorporating a variety of experimental data also can help reduce ill-posedness by requiring the model to reproduce multiple behaviors. In particular, the post-castration dynamics data represent measurements of several different model variables in time, so that the resulting model simulations capture the biology over several time scales and complexity scales ranging from the receptor level up to the tissue and systemic levels.
The final step involved solving a third estimation problem for all parameters from the first two problems using the full model. Since the pharmacokinetic parameters were estimated using a submodel, it was important to re-estimate all parameters together. The pharmacokinetic The ability of the model to be expanded allows for the potential to address a broad range of issues associated with male reproductive function, especially prostate function and maintenance. One major objective is to characterize the effects of prepubertal exposure to antiandrogens, such as vinclozolin, in male rats because this has been proposed as a bioassay for detecting compounds with endocrine disrupting activity (47) . This will involve adapting the model to describe the normal pubertal maturation process, as well as the effects on that process that result from prepubertal vinclozolin exposure. Such an elaboration will require modeling prepubertal regulation dominated by androstanediol and the transition to adult androgen regulation dominated by T and DHT. These modeling efforts will provide a quantitative means for understanding the dynamic changes in the male reproductive endocrine system that occur during pubertal development, such as tissue growth, androgen production in the testes and concentrations of androgens and binding proteins (2, 3, 13, 14, 34, 44, 47) . The pubertal model also will aid in quantitatively describing how antiandrogens interfere with these pubertal changes, enhance the understanding of the dose-response relationships, and improve accuracy in the risk assessment of these chemicals (5). Mendel CM. The free hormone hypothesis. Distinction from the free hormone transport hypothesis. J Androl 13: 107-116., 1992.
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